Compounds > zd 6126
Page last updated: 2024-11-11

zd 6126

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9896434
CHEMBL ID257662
SCHEMBL ID1285000
MeSH IDM0425290

Synonyms (27)

Synonym
zm-445526
azd 6126
ang 453
zd-6126
zm 445526
zd 6126
zd6126
CHEMBL257662
azd-6126
ang-453
n-acetylcochinol-o-phosphate
acetamide, n-((5s)-6,7-dihydro-9,10,11-trimethoxy-3-(phosphonooxy)-5h-dibenzo(a,c)cyclohepten-5-yl)-
gbo3s6m9w7 ,
219923-05-4
unii-gbo3s6m9w7
n-acetylcolchicinol dihydrogenphosphate
BCP9000366
azd6126, ang453
BCP0726000110
phosphoric acid mono-(5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5h-dibenzo(a,c)cyclohepten-3-yl) ester
zd 6126 [who-dd]
SCHEMBL1285000
DB11872
(5s)-5-acetamido-9,10,11-trimethoxy-6,7-dihydro-5h-dibenzo[a,c][7]annulen-3-yl dihydrogen phosphate
DTXSID20944593
Q8062996
[(8s)-8-acetamido-13,14,15-trimethoxy-5-tricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,5,11,13-hexaenyl] dihydrogen phosphate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Close collaboration with cardiology colleagues for early indicators of serious cardiac adverse events will likely minimize toxicity while optimizing the therapeutic potential of VDAs and ultimately enhancing patient outcomes."( Cardiovascular toxicity profiles of vascular-disrupting agents.
Lenihan, DJ; Subbiah, IM; Tsimberidou, AM, 2011)		0.37

Compound-Compound Interactions

ExcerptReferenceRelevance
" ZD6126 caused marked vessel destruction through loss of endothelial cells and thrombosis, substantially increasing the level of necrosis seen when combined with radiation therapy."( Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft
Bianco, AR; Bianco, C; Bianco, R; Bunn, P; Ciardiello, F; Cionini, L; D'Armiento, FP; Damiano, V; Melisi, D; Mignogna, C; Raben, D; Tortora, G, 2004)		0.32
" The antitumor effect of ZD6126 can be increased in combination with cisplatin or radiation therapy, although the precise mechanism of this enhancement has not been demonstrated."( Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Blakey, DC; Goto, H; Matsumori, Y; Ogawa, H; Sone, S; Yano, S, 2004)		0.32
" ZD6126 alone induced apoptosis of tumor-associated endothelial cells in tumors, and the extent of apoptosis was increased 2-fold in combination with cisplatin."( Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Blakey, DC; Goto, H; Matsumori, Y; Ogawa, H; Sone, S; Yano, S, 2004)		0.32
"These data suggest that the antimetastatic effect of the vascular-targeting agent ZD6126 can be increased by use in combination with cisplatin, which increases the incidence of endothelial cell apoptosis."( Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Blakey, DC; Goto, H; Matsumori, Y; Ogawa, H; Sone, S; Yano, S, 2004)		0.32
" Thus, the use of angiogenesis inhibitors in combination with radiation therapy should help to overcome the limitations of each leading to enhanced efficacy and diminished toxicity."( Radiation combined with antiangiogenic and antivascular agents.
O'Reilly, MS, 2006)		0.33
"The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies."( Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
Bonezzi, K; Frapolli, R; Giavazzi, R; Kuhn, E; Martinelli, M; Riccardi, E; Ryan, AJ; Taraboletti, G; Zucchetti, M, 2007)		0.34
" Rats with implanted liver tumors were randomized into four treatment groups: 1) Zd6126 (Zd); 2) Thalidomide (Tha); 3) Zd in combination with Tha (ZdTha); and 4) controls."( Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI.
Chen, F; Cona, MM; De Geest, B; De Keyzer, F; Feng, Y; Jiang, Y; Li, J; Marchal, G; Ni, Y; Oyen, R; Verfaillie, C; Wang, H; Yu, J; Zheng, K, 2012)		0.38

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies showed that these effects were seen at a dose 8- to 16-fold lower than the maximum tolerated dose, demonstrating that ZD6126 has a wide therapeutic margin in these mouse models."( Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Ashton, SE; Blakey, DC; Davis, PD; Hughes, GD; Ryan, AJ; Walker, M; Westwood, FR, 2002)		0.31
"3-fold increase in the slope of the radiation dose-response curve."( Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response.
Horsman, MR; Murata, R, 2003)		0.32
" This study investigated the duration of the response to the vascular targeting agent, ZD6126, of the GH3 prolactinoma, in which efficacy and dose-response have previously been demonstrated."( Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model.
Blakey, DC; Griffiths, JR; Howe, FA; McIntyre, DJ; Peers, IS; Robinson, SP; Ryan, AJ; Waterton, JC, )		0.13
" at up to maximum tolerated doses using subacute (0 to 20 mg/kg/d for 5 days) and chronic (0 to 10 mg/kg/d for 5 days, repeated monthly for 6 months) dosing regimens."( Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the rat.
Allen, SL; Arezzo, JC; Gould, S; Horner, SA; Noakes, JP; Rattray, NJ; Zotova, E, 2004)		0.32
" Our findings suggest that the optimal therapeutic benefit of ZD6126 plus radiation in human glioblastoma may require multiple dosing in combination with a nitric oxide synthase inhibitor, to be scheduled following radiotherapy."( Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.
Burd, R; Daskalakis, C; Dicker, AP; Marero, N; McCue, P; Ryan, A; Wachsberger, PR, 2005)		0.33
" In single and multiple dosing experiments, mice received ZD6126, gemcitabine, a combination of both agents, or no treatment."( Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.
Barge, A; Bruns, CJ; Friedrich, M; Jauch, KW; Kleespies, A; Köhl, G; Ryan, AJ, 2005)		0.33
" There was no difference in the pharmacokinetics of ZD6126 phenol upon repeat administration or between the two dosing regimens."( Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.
Barge, AJ; Boerner, SA; DelProposto, ZS; DeLuca, PA; Evelhoch, JL; Gadgeel, SM; Jones, HK; LoRusso, PM; Wheeler, C; Wozniak, A, 2008)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID320103Half life in human assessed as ZD-6126-phenol2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Vascular disrupting agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's58 (79.45)29.6817
2010's15 (20.55)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.91 (24.57)
Research Supply Index4.37 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.63%)5.53%
Reviews11 (14.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other63 (82.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
atenolol
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.		2.0310ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
hypericin
[no description available]		2.0610
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		2.0310C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		2.4820phthalimides;
piperidones
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		4.3730L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		2.0210pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		3.2860alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		2.0210mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		3.1110xanthene
perylene
Perylene: A 20-carbon dibenz(de,kl)anthracene that can be viewed as a naphthalene fused to a phenalene or as dinaphthalene. It is used as fluorescent lipid probe in the cytochemistry of membranes and is a polycyclic hydrocarbon pollutant in soil and water. Derivatives may be carcinogenic.. perylene : An ortho- and peri-fused polycyclic arene comprising of five benzene rings that is anthracene in which the d,e and k,l sides are fused to benzene rings.		2.0610ortho- and peri-fused polycyclic arene;
perylenes
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		3.1250azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
thiazoles
[no description available]		2.02101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
deoxycytidine
[no description available]		2.0210pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		3.8230taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		2.0210organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		2.0210organic bromide saltcolorimetric reagent;
dye
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		2.05102-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
combretastatin
combretastatin: cytotoxic principle from South African tree COMBRETUM caffrum; structure given in first source; acts at COLCHICINE site of TUBULIN		4.3730
gefitinib
[no description available]		2.4320aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
vadimezan
vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.		7.36100monocarboxylic acid;
xanthones		antineoplastic agent
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		2.0210secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
n-acetylcolchinol
N-acetylcolchinol: structure		2.7130
nitroarginine
Nitroarginine: An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6). N(gamma)-nitro-L-arginine : An L-arginine derivative that is L-arginine in which the terminal nitrogen of the guanidyl group is replaced by a nitro group.		2.0210guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		7.2790stilbene
pyrophosphate
Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.		4.6930diphosphate ion
zd 6474
CH 331: structure in first source		2.4220aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
tx 402
3-amino-2-quinoxalinecarbonitrile: has antineoplastic activity; structure in first source		2.0210
fosbretabulin
fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source		6.7370
boron
Boron: A trace element with the atomic symbol B, atomic number 5, and atomic weight [10.806; 10.821]. Boron-10, an isotope of boron, is used as a neutron absorber in BORON NEUTRON CAPTURE THERAPY.		2.0210boron group element atom;
metalloid atom;
nonmetal atom		micronutrient
gadolinium dtpa
Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)		3.3520gadolinium coordination entityMRI contrast agent
soblidotin
soblidotin: a dolastatin 10 derivative; RN refers to (2S-(1(1R*(R*),2S*),2R*(1S*,2S*)))-isomer; structure given in first source. soblidotin : A tetrapeptide derivative of dolastatin 10. It is an inhibitor of tubulin polymerization which exhibits potent antitumor activity.		4.0620tetrapeptideantineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent
ac 7700
AC 7700: a vascular disrupting agent; structure in first source		4.3730
oxi 4503
Oxi 4503: diphosphate prodrug of cambretastatin A1		4.6930
verubulin
verubulin: antineoplastic; a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps; structure in first source		2.0610
hoe 33342
bisbenzimide ethoxide trihydrochloride: benzimidazole fluorescent dye		4.0450
piperidines
Piperidines: A family of hexahydropyridines.		2.4220
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		2.0210
ganciclovir
[no description available]		2.03102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
tirapazamine
Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.		2.4320aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		09.5192
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		09.5192
Cancer of Gastrointestinal Tract
[description not available]		03.0110
Angiogenesis, Pathologic
[description not available]		07.82300
Experimental Hepatoma
[description not available]		02.4820
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		06.73210
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		02.4820
Cancer of Colon
[description not available]		02.4620
Colonic Neoplasms
Tumors or cancer of the COLON.		02.4620
B16 Melanoma
[description not available]		02.0410
Cancer of Liver
[description not available]		02.7430
Liver Neoplasms
Tumors or cancer of the LIVER.		02.7430
Adenocarcinoma, Basal Cell
[description not available]		03.2860
Adenocarcinoma Of Kidney
[description not available]		02.4420
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.2860
Cancer of Kidney
[description not available]		02.4420
Cancer of Lung
[description not available]		04.260
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		03.2860
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		14.4420
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.4420
Lung Neoplasms
Tumors or cancer of the LUNG.		04.260
Benign Neoplasms, Brain
[description not available]		02.4420
Astrocytoma, Grade IV
[description not available]		02.4420
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.4420
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.4420
Cancer of Prostate
[description not available]		02.0710
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0710
Malignant Melanoma
[description not available]		02.0110
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.0110
Carcinoma, Epidermoid
[description not available]		03.1250
Experimental Neoplasms
[description not available]		04.9550
Cancer of Pharynx
[description not available]		02.0110
Experimental Mammary Neoplasms
[description not available]		02.4220
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		03.1250
Pharyngeal Neoplasms
Tumors or cancer of the PHARYNX.		02.0110
Disease Exacerbation
[description not available]		02.4220
Cancer of Pituitary
[description not available]		02.4320
Adenoma, Prolactin-Secreting, Pituitary
[description not available]		02.7130
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		02.7130
Pituitary Neoplasms
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.		02.4320
Anoxemia
[description not available]		03.6330
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		03.6330
Metastase
[description not available]		02.9340
Peritoneal Carcinomatosis
[description not available]		02.0210
Cancer of Stomach
[description not available]		02.0210
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		14.9340
Peritoneal Neoplasms
Tumors or cancer of the PERITONEUM.		02.0210
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.0210
Nervous System Disorders
[description not available]		02.0210
Nervous System Diseases
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.		02.0210
Carcinoma, Non-Small Cell Lung
[description not available]		03.3420
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		03.3420
Kaposi Sarcoma
[description not available]		02.0210
Sarcoma, Kaposi
A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.		02.0210
Sarcoma, Epithelioid
[description not available]		02.9410
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		02.9410
Cancer of Head
[description not available]		02.7230
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		02.7230
Lymph Node Metastasis
[description not available]		02.0210
Cancer of Pancreas
[description not available]		02.0210
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.0210
Cancer of Cervix
[description not available]		02.0310
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.0310
Animal Mammary Carcinoma
[description not available]		02.0310
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0310
Breast Cancer
[description not available]		02.0310
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0310
Blood Pressure, High
[description not available]		02.0310
Tachyarrhythmia
[description not available]		02.0310
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.0310
Tachycardia
Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.		02.0310
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.0410
EHS Tumor
[description not available]		02.0110